T he recent paradigm shift in the treatment of critically injured patients suffering massive bleeding has seen a fundamental change from crystalloid and red blood cell (RBC)-based resuscitation toward the early delivery of balanced blood components (plasma, platelets, and RBCs). 1 This change in transfusion practice has resulted in substantially improved outcomes for trauma patients. A recent large, randomized clinical trial has shown that early balanced administration of blood products is crucial, with a particular emphasis on the rapid delivery of plasma. 2 Plasma-based resuscitation has been shown to help reverse trauma-induced coagulopathy, restore volume deficits, repair endothelial permeability, and mitigate inflammatory responses after trauma. [1] [2] [3] [4] [5] [6] [7] The most recent recommendations from the American College of Surgeons state that liquid-state plasma should be readily available (within 15 minutes) for providing balanced resuscitation during massive transfusion. 8 Likewise, the United Kingdom has endorsed the rapid and balanced transfusion approach for bleeding patients. 9 These recommendations have resulted in the demand for plasma ready for immediate use in emergency centers, with some centers extending this approach to the prehospital setting. These protocols have created new logistic opportunities for blood banks dispensing components to trauma departments. Blood bank inventories most commonly supply plasma as fresh frozen plasma (FFP) or plasma frozen within 24 hours (FP24) and, less commonly, thawed plasma (TP) and liquid plasma (LP). FFP is frozen within 8 hours of collection and can be stored at 48C for up to 24 hours after thawing. FFP can be relabeled as TP, which can be kept for a further 4 days. LP is never FP, which has the longest shelf-life (up to 26 days) but is the least commonly used of these plasma products.
In the March issue of TRANSFUSION, Backholer and colleagues elegantly compare the hemostasis parameters of TP with those of LP and the impact of storage over time. 10 Their data indicate that, for 7 days of storage, LP demonstrated more rapid initiation of coagulation despite minor decreases in clotting factor levels. However, overall differences in factor levels and coagulation parameters were negligible, suggesting there is little effect of freezing and thawing on the hemostatic capacity of plasma. Importantly, they also showed that LP coagulation potential was stable for up to 7 days but started showing protein degradation after 11 days of storage. Furthermore, LP stored for 14 to 28 days exhibited evidence of contact activation as a result of cold storage. The overall conclusion was that LP and TP are comparable in their ability to promote hemostasis with recommended use up to 14 days, although the appropriate shelf-life for LP remains to be definitively established. Their report provides a thought-provoking response to the requirement for rapidly available, balanced transfusion.
TIME AND WASTAGE
In most emergency centers, FFP is thawed on demand to avoid wastage. However, thawing plasma takes approximately 30 to 45 minutes. Recent studies have documented the importance of these first 30 to 45 minutes in the hospital, representing the steepest part of the mortality curve. 11 The time to hemorrhagic death is approximately 2 hours, and 85% of these deaths occur in the first 6 hours after admission. 11, 12 Waiting while FP is ordered, thawed, transported to the bedside, paperwork checked, and then infused likely contributes to increased hemorrhagic deaths. These are factors that are modifiable, under our control, and can be addressed today with approved products. For the most critical patients, having LP or TP plasma prepositioned at the point of care decreases death. Recent data suggest that delaying transfusion by 5 minutes results in increased mortality. 13 Thus, the time required to thaw plasma could literally be lifethreatening for a patient with massive hemorrhage. Studies have described a significant delay in delivery of plasma due to thawing. 14, 15 Radwan and colleagues describe moving thawed plasma from the blood bank to the emergency department, resulting in decreased time to infusion while improving outcomes. 14 PROPPR trial, with a reported 1.9% total plasma wastage. 16 Similarly, we had previously reported a 1.9%
wastage while transfusing TP and LP on helicopters. 17 Finally Wehrli and colleagues reported that keeping a stock of TP actually decreased wastage and saved money. 18 Utilizing TP and LP is a patient-centered approach associated with improved outcomes and can be accomplished with optimal inventory-management concepts.
TP VS LP
Nonetheless, from a logistic perspective, LP is potentially far superior to TP, because there is no freezing process required, it is available for immediate transfusion, and has a shelf-life of 26 days rather than 5 days. However, does it have the same hemostatic capacity as TP?
Is storage for such an extended period of time truly without significant consequences to the overall hemostatic quality? Previous reports agree with the finding that LP is equal, if not superior, to TP in terms of the ability to promote hemostasis. 19 First, and as the authors of the current paper discuss, LP is abundant in platelet-derived microparticles (MPs), which provide a lipid-rich surface for the initiation and propagation of thrombin generation. This potential was reflected in the ability of LP to rapidly form thrombin despite the reduced coagulation factor levels. These findings, in conjunction with other reports demonstrating the clinical importance of MPs in promoting hemostasis after trauma, bring to light the important role of plasma in replacing not only lost coagulation factors but also key cellular components that are critical for supporting hemostasis. Our group recently showed that MP type and quantity are important predictors of transfusion requirements and outcomes in trauma patients. 20 Importantly, Matijevic and coworkers also demonstrated that coagulopathic trauma patients have lower levels of both platelet-derived and tissue factor-bearing MPs than noncoagulopathic patients. 21 This observation drives home the necessity of introducing platelets early in the resuscitation regime and suggests that the development of a separate MP component or concentrate could provide a new therapeutic avenue for those patients in dire need of rapid reversal of coagulopathy. In addition to the superior ability of LP to provide cellular hemostatic support in the form of platelets and MPs, LP has been shown to be equally as effective at repairing or reversing the endotheliopathy of trauma. In an in vitro model, Cao and colleagues demonstrated that LP was able to reduce endothelial cell permeability after tumor necrosis factor-a activation similar to TP. This capability was retained even when LP was stored up to 28 days. 22 Thus, evidence from the laboratory suggests that LP provides better vascular and hemostatic support than TP.
STORAGE AND DEGRADATION
Several studies have described the negative impact of storage on TP, even at the currently accepted shelf-life of 5 days. Side effects of storage include reduced coagulation protein levels, diminished ability to generate thrombin, and a decline in procoagulant MP levels. [23] [24] [25] Furthermore, stored TP is less effective at reversing endothelial cell permeability and promoting endothelial cell migration. 26, 27 Notably, increased storage of TP has been associated with poor outcomes in in vivo models.
Pati and colleagues demonstrated in a rat model of hemorrhagic shock that resuscitation with freshly thawed plasma was more effective at preventing physiologic decompensation than TP at 5 days. 26 Our group also showed that, when pretreated with either fresh TP or TP stored for 5 days prior to uncontrolled hemorrhage, all rats receiving fresh TP survived hemorrhage and resuscitation compared with only 54% survival in rats receiving stored TP.
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LOGISTICS
Collectively, the data reported by Backholer and coworkers and evidence from the literature overwhelmingly suggests that storage of TP and LP is associated with degradation. What has become clear over the last few years is the essential element of near-immediate delivery of balanced blood products to the massively bleeding patient. This clinical emergency is one of those times when minutes really do count. The substantial logistic challenges associated with making FP readily available in the emergency setting force us to identify a safe and effective alternative to FFP for trauma. More and more trauma centers are maintaining an inventory of TP and LP. Very little data exist comparing the hemostatic capacity of TP and LP, making the findings of Backholer and colleagues highly relevant to solving blood banking challenges for transfusion in trauma. However, the most important question concerning TP versus LP has yet to be answered: Which therapeutic option is associated with better outcomes in rapidly hemorrhaging trauma patients? Countries with robust hemovigilance programs will likely provide the most conclusive evidence on how these products affect patient outcomes. 29 Allen and coworkers recently showed in a retrospective analysis that an institutional change making LP readily available for transfusion resulted in improved, early, balanced delivery of blood products. 30 These data reinforce our support of LP use in the trauma setting. The Texas Trauma Institute has moved to a resuscitation protocol in which plasma is given first and platelets are given early, with a goal of achieving an early 1:1:1 balance between plasma, platelets, and red blood cells. Once balanced resuscitation is achieved and the rate of transfusion slows, we shift to a goal-directed approach based on laboratory values (primarily thromboelastography) to maintain appropriate hemostatic resuscitation moving forward. 31 For this clinical stability to happen as soon as possible for EVERY patient in need of transfusion, we keep an inventory of universal-donor TP available in the emergency department and universal-donor LP in transport vehicles (ground and air) to eliminate the need to thaw in transport and minimize the need to rotate expiring TP. Still, LP is not without its potential drawbacks. Based on their data, Backholer and colleagues recommend a shelf-life for LP of 14 days or less to avoid significant coagulation protein degradation and contact activation. The clinical ramifications of contact activation are not well understood, as they discuss. Conceivably, however, even a low level of cold-induced contact activation could further reduce the coagulation factor content through the generation of thrombin, making it less hemostatically robust after transfusion.
NEW AND OLDER PRODUCTS
The future may lie in even newer plasma products, such as dried plasma. Such components are shelf-stable for long periods of time and can be reconstituted at a moment's notice. This stability and easy reconstitution make these products ideal not only for emergency departments, operating rooms, and intensive care units but also in transport vehicles and remote or combat settings. Encouraging data from multiple large animal models show that lyophilized plasma is a comparable product to FFP after traumatic brain injury and hemorrhagic shock. [32] [33] [34] [35] Recently, several observational studies have supported the use of various formulations of dried plasma. Although they are not approved for use in the United States, these products are in routine use in multiple locations around the world, combining the utility of room-temperature storage, rapid reconstitution, and improved clinical outcomes with early plasma transfusion. [35] [36] [37] [38] [39] [40] [41] [42] Finally, in a move back to the resuscitation fluid used for 50 years, many centers are moving toward the use of whole blood as the ultimate, balanced resuscitation fluid for bleeding patients. 43 
CONCLUSIONS
Until dried plasma products are approved, LP with a shelf-life of 14 days seems to be a superior product. It appears to be acceptable from a hemostatic perspective and is certainly a logistically superior and acceptable alternative to TP, FFP, and PF24. In conclusion, every minute-every second-counts when patients are bleeding. We must be willing to accept potential shortcomings in the quality of TP or LP because, in an emergency setting in which a patient is exsanguinating, it is more than good enough and may be our best option.
